AlphAIalphai — Financial news for AI agents
investing.comAUG 202 min read$RYTM

This stock is TD Cowen’s Top Pick After Strong Q2

TD Cowen named Rhythm Pharmaceuticals (RYTM) its top pick, citing strong Q2 results and pipeline progress. Imcivree revenue hit $71.3M, up 19% QoQ and 47% YoY, beating estimates. The company plans to advance RM-718 into a pivotal trial. TD Cowen set a $130 price target and Buy rating.

Original reporting
investing.com
Published Aug 20, 2026, 5:53 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 6:02 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$RYTM
Bullish
medium confidence
Mentioned
$RYTM
Relevance
6/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$RYTMBullishMed
01

Why it matters

The combination of financial beat and clinical progress provides a catalyst for short‑term price appreciation.

02

Market read

Positive earnings and data could lift Rhythm and peer obesity‑treatment stocks.

03

What to watch

European revenue decline and modest trial size could temper enthusiasm.

Relevance 6/10Novelty 7/10Timing: post‑market

Background

TD Cowen issued a Buy rating with a $130 price target after Rhythm's Q2 earnings beat and early trial results.

Company-level read

Ticker impact

$RYTMBullishMedium confidence
Context

Rhythm Pharmaceuticals reported Q2 revenue beat and disclosed proof-of-concept data for its MC4R agonist program.

Expected impact

Potential upside as analysts raise price target to $130.

Evidence & confidence

Revenue beat and positive trial data often drive short‑term buying pressure in biotech.

Market effects

Sector

Strengthens outlook for obesity‑treatment biotech sector.

Regional

U.S. biotech investors may reallocate toward Rhythm.

Global

Limited to niche obesity‑therapy market.

Counterpoint

What could challenge this read

Trial data may not translate to commercial success; valuation could be overstretched.

Key entities

  • Company
    Rhythm Pharmaceuticals

    Biotech firm developing MC4R agonists for obesity disorders.

  • Research Firm
    TD Cowen

    Equity research analyst that issued the recommendation.

Read at source← All news

Also covered by

1 outlet

Related articles

AUG 24
$RYTMHighAI 8/10

Rhythm Wins Japan Nod For IMCIVREE As First Treatment For Acquired Hypothalamic Obesity; Stock Up

Rhythm Pharmaceuticals (RYTM) received Japanese approval for IMCIVREE to treat acquired hypothalamic obesity, a rare condition. The approval follows a Phase 3 trial showing significant BMI reduction. Rhythm estimates 5,000-8,000 people in Japan have this condition. The UK also expanded IMCIVREE's authorization. RYTM stock is up 0.99% to $110 at close, down 0.72% in pre-market.

rttnews.com2 min
AUG 11
$RYTMMedAI 8/10

Rhythm Pharmaceuticals (RYTM) Q2 2026 Earnings Call Transcript

Rhythm Pharmaceuticals (RYTM) reported Q2 2026 revenue of $71.3M, up 19% sequentially. U.S. revenue was $51M, up 38% sequentially, while international sales fell to $20.3M due to a $3.8M French retrospective charge. Management said cash and short-term investments were $330.9M, guiding FY26 non-GAAP OpEx to $363M-$397M and R&D to $175M-$195M.

fool.com6 min
AUG 5
$RYTMMed

Rhythm Pharmaceuticals reports RM-718 trial results in obesity

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported preliminary Phase 2 results for RM-718, a once-weekly MC4R agonist, in acquired hypothalamic obesity. In 7 patients completing 16 weeks, mean BMI fell 11.6% from baseline. The company cited comparisons versus bivamelagon (10.1% at 14 weeks) and setmelanotide (10.1% at 16 weeks). Mild injection-site hyperpigmentation and common GI side effects were reported.

investing.com4 min
AUG 4
$RYTMMed

Rhythm Pharmaceuticals Reports Positive Signal For RM-718 In Rare Obesity Disorder

Rhythm Pharmaceuticals (RYTM) reported preliminary Phase 2 results for RM-718, an investigational once-weekly MC4R agonist for acquired hypothalamic obesity. In 11 enrolled patients, 7 reached 16 weeks. Interim data showed mean BMI down 11.6% from baseline, with two mild injection-site hyperpigmentation cases and generally tolerable side effects. Two discontinued; eight remained on treatment as of mid-July 2026.

rttnews.com4 min